| Identification | Back Directory | [Name]
N-(5-ADAMANTANE-1-YL-METHOXY)-PENTYL-DEOXYNOJIRIMYCIN | [CAS]
216758-20-2 | [Synonyms]
AMP-DEOXYNOJIRIMYCIN
ADAMANTANE-PENTYL-DNM
AMP-Deoxynojirimycin Exclusive
AMP-Deoxynojirimycin - Solution in ethanol
N-(5-AdaMant-1-yl-Methoxy)pentyl DeoxynojiriMycin
N-(5-ADAMANTANE-1-YL-METHOXY)-PENTYL-DEOXYNOJIRIMYCIN
2R-(HYDROXYMETHYL)-1-[5-(TRICYCLO[3.3.2.13,7]DEC-1-YLMETHOXY)PENTYL]-3R,4R,5S-PIPERIDINETRIOL
3,4,5-Piperidinetriol, 2-(hydroxymethyl)-1-[5-(tricyclo[3.3.1.13,7]dec-1-ylmethoxy)pentyl]-, (2R,3R,4R,5S)- | [Molecular Formula]
C22H39NO5 | [MDL Number]
MFCD01863330 | [MOL File]
216758-20-2.mol | [Molecular Weight]
397.55 |
| Chemical Properties | Back Directory | [Boiling point ]
569.9±50.0 °C(Predicted) | [density ]
1.214±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 50 mg/ml; DMSO: 50 mg/ml; Ethanol: 30 mg/ml; Ethanol:PBS(pH 7.2) (1:1): 0.5 mg/ml | [form ]
powder | [pka]
13.72±0.70(Predicted) | [color ]
white to beige | [InChI]
1S/C22H39NO5/c24-13-18-20(26)21(27)19(25)12-23(18)4-2-1-3-5-28-14-22-9-15-6-16(10-22)8-17(7-15)11-22/h15-21,24-27H,1-14H2/t15-,16+,17-,18-,19+,20-,21-,22?/m1/s1 | [InChIKey]
XVYLNHVEAOOEGI-OIPNBASOSA-N | [SMILES]
O[C@@H]1[C@H](N(C[C@@H]([C@H]1O)O)CCCCCOCC2(C3)C[C@@H](C4)C[C@H]3C[C@@H]4C2)CO |
| Hazard Information | Back Directory | [Chemical Properties]
Off White Foam | [Uses]
A powerful inhibitor of the non-lysomal glucoceramidase at nanomolar concentrations. At these low concentrations, the lysosomal glucocerebrosidase and a-glucosidase, the glucoceramide synthetase, and the N-linked glycantrimming a-glucosidases of the endoplasmic reticulum are not affected. | [Biological Activity]
AMP-deoxynojirimycin (AMP-DNM) is an orally available iminosugar th at acts as a reversiblepotent and selective inhibitor against the non-lysosomal glucosylceramidase GBA2 (IC50 = 1.7 nM) over the glucosylceramide synthase (GCSUGCG)ER alpha-glucosidasesthe lysosomal glucocerebrosidase GBA (IC50 = 0.16 μM) and alpha-glucosidase GAA (IC50 = 0.87 μM). AMP-DNM selectively inhibits cellular GBA2 in cultures (GBA2/GBA IC50 = 0.3 nM/100 nM; human melanoma cells) and exhibits in vivo therapeutic efficacy in murine models of obesity (100 mg/kg/day p.o.) and colitis (10-50 mg/kg/day via i.p. or 1.25-6.25g/kg chow). |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList1701258/0_EN.htm |
|